过继性免疫治疗对非小细胞肺癌患者外周血T细胞亚群的影响  

Effects of Adoptive Immunotherapy on T Cell Subsets of Peripheral Blood in Non-small Cell Lung Cancer Patients

作　　者：王婷婷[1] 王郁[1] 贾云泷[1] 王雪晓 王佳丽[1] 吕微[1] 段玉青[1] 刘丽华[1] 

机构地区：[1]河北医科大学第四医院生物治疗科,石家庄050035

出　　处：《肿瘤防治研究》2015年第4期345-349,共5页Cancer Research on Prevention and Treatment

基　　金：国家自然科学基金青年科学基金(81201607);河北省自然科学基金面上项目(H2012206135)

摘　　要：目的研究细胞因子诱导的杀伤(cytokine-induced killer,CIK)细胞治疗对非小细胞肺癌(non-small cell lung cancer,NSCLC)患者外周血T细胞亚群及一般情况的影响。方法采集非小细胞肺癌患者外周血,常规方法体外扩增CIK细胞,分三次回输患者体内,流式细胞仪检测非小细胞肺癌患者治疗前与治疗3次后T细胞亚群的变化,分析其与健康对照组相比外周血T细胞亚群的差异,并观察CIK细胞治疗前后患者一般情况变化。结果与对照组相比,NSCLC患者外周血中CD3+T细胞比例、CD3+CD4+T细胞比例、CD4+/CD8+比值显著下降(P<0.05),CD3+CD8+T细胞比例显著升高(P<0.05)。CIK细胞治疗后与治疗前,CD3+T细胞比例、CD3+CD4+T细胞比例、CD4+/CD8+T细胞比值显著升高(P<0.05),CD3+CD8+T细胞比例显著降低(P<0.05)。CIK细胞治疗后与对照组相比,CD3+T细胞比例、CD4+/CD8+T细胞比值显著下降(P<0.05)。CD3+CD4+T细胞比例、CD3+CD8+T细胞比例升高,但差异无统计学意义(P>0.05)。CIK细胞治疗前Tregs较对照组显著升高(P<0.05)。CIK细胞治疗后与治疗前相比,Tregs比例显著下降(P<0.05)。结论 CIK细胞输注治疗可以增强NSCLC患者的免疫功能,并改善患者的一般情况,提高生活质量,且未见明显不良反应。Objective To investigate the effect of cytokine-induced killer(CIK) cells therapy on T cell subsets in the peripheral blood and general condition of non-small cell lung cancer(NSCLC) patients. Methods Peripheral blood mononuclear cells(PBMCs) were collected from the peripheral blood of NSCLC patients. CIK cells were expanded by classical protocol, re-infused to the patients once a day for 3 consecutive days. Before and after 3 courses of CIK cells therapy, the changes of T cell subsets were assessed by flow cytometry, and the difference of T cell subsets between patients and healthy subjects were analyzed. General condition of NSCLC patients was observed before and after the therapy. Results Compared with the control group, the expression of CD3+T cells, CD3+CD4+T cells, CD4+/CD8+ T cells in the peripheral blood of NSCLC patients were significantly decreased(P<0.05), the expression of CD3+CD8+ T cells were significantly increased(P<0.05). After the CIK cells therapy, the expression of CD3+ T cells, CD3+CD4+ T cells, CD4+/CD8+ T cells were significantly increased(P<0.05); while the expression of CD3+CD8+ T cells were significantly decreased(P<0.05). Compared with the control group, the expression of CD3+ T cells and CD4+/CD8+ T cells were significantly decreased(P<0.05) after CIK cells therapy; the expression of CD3+CD4+ T cells and CD3+CD8+T cells were increased(P>0.05). Tregs in NSCLC patients before CIK cells therapy were significantly increased compared with the control group(P<0.05), and Tregs in stage Ⅲ~Ⅳ patients were significantly higher than that in stage Ⅰ~ Ⅱ patients(P<0.05). After CIK cells therapy, Tregs in stage Ⅰ~ Ⅱ and stage Ⅲ~Ⅳ patients were significantly decreased compared with those before CIK cells therapy(P<0.05). After CIK cells therapy, Tregs in stage Ⅰ~ Ⅱ patients were significantly lower than that in the control group(P<0.05). Tregs in stage Ⅲ~Ⅳ patients were still higher than that in the control group(P>0.05). Conclusion CIK cells therapy could enhance the immunity

关 键 词：细胞因子诱导的杀伤细胞 非小细胞肺癌 免疫功能 调节性T细胞 

分 类 号：R734.2[医药卫生—肿瘤]